OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE is advancing an “Immunotherapy 2.0” future by leveraging MAbSilico’s artificial intelligence-powered software solutions and…